An interventional study of Application of a vascular restriction device during resistance training in Heart Failure and Ventricular Function, Left, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 448 studies in Heart Failure with a site in France — 90 open to participants now, 116 under way, 16 of them phase 3. Heart Failure · France.
Among the 448 studies in Heart Failure with a site in France, this one is the 231st largest by planned enrollment of the 282 interventional ones that give a count, is one of 29 that started in 2025, is one of 176 with no phase, reaches primary completion later than 65 of the 115 other live ones, and was the 407th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →90 of the 448 studies in Heart Failure with a site in France are open now. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Poitiers University Hospital · Sites in France
Ages 18–90
University Hospital, Montpellier · Sites in France
Ages 18+
Oslo University Hospital · Sites in France, United States, Belgium and 7 more countries
Ages 18+
AstraZeneca · Sites in France, United States, Argentina and 29 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
448 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 28 · Phase 3 70 · Phase 4 15
First in 1983; this study’s year is marked. 29 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 38 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 196 across the 282 interventional studies, 321 across the 161 observational. Of the 290 that completed or were terminated, 74 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
184 of 448 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
Centre Hospitalier Universitaire de Nīmes has 5 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
28 of the studies in Heart Failure with a site in France that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020263Phase 3Pr Bruno LEVYEffect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock | 2027-02-03 |
| NCT05879276Phase 3Central Hospital, Nancy, FranceEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. | 2027-03-16 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06518694Phase 3Assistance Publique - Hôpitaux de ParisBeta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction | 2027-10 |
Add all 28 to your calendar (.ics) → With an account.
Among the 448 studies in Heart Failure with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Exercise is essential in cardiac rehabilitation for heart failure patients.Aerobic training and resistance training are both recommended. Resistance training improves muscle mass and strength and also improves the remodeling of cardiac function, thus reducing exercise intolerance in these patients. However, to obtain these adaptations, resistance training must be done at moderate to high intensities, which cannot always be sustained by the most fragile and deconditioned patients, such as those with reduced ejection fraction (Heart failure with reduced Ejection Fraction).
Blood flow restriction (BFR) by vascular occlusion training is an interesting alternative to conventional resistance training for these deconditioned patients. Preclinical and clinical studies have shown that, for low-intensity regimens, resistance training and blood flow restriction by vascular occlusion improves muscle strength and left ventricular function, unlike resistance training alone. Tissue hypoxemia, initiated by vascular occlusion and exacerbated by maintenance of exercise, is a key element in the peripheral adaptations documented in blood flow restriction, triggering a cascade of signaling pathways involving neurohumoral factors in particular, with effects both locally (i.e. striated skeletal muscle) and remotely, on the myocardium among others. The feasibility and safety of blood flow restriction in heart failure patients has been well demonstrated. Left ventricle ejection fraction remains a very global functional index, with poor reproducibility influenced by cardiac load conditions, making it impossible to draw any conclusions as to possible improvements in myocardial function, linked to changes in intrinsic tissue decontractility/relaxation properties. New cardiac imaging techniques like Speckle Tracking Echography have made it possible to assess the effects of blood flow resistance on myocardial function but so far no studies have used these tools to compare the effects of BFR+resistance training and resistance training alone on myocardial function in heart failure patients. It is suggested that resistance training combined with blood flow resistance could further improve cardiac and muscular function compared with resistance training alone, by activating neurohumoral mediators, like certain micro ribonucleic acids.
Physical exercise is an essential part of cardiac rehabilitation for heart failure patients. In addition to aerobic training, resistance training is now recommended by scientific societies. Clinical studies report that resistance training contributes not only to peripheral reconditioning, with improved muscle mass and strength, but also to central reconditioning, with improved remodeling and cardiac function, thus reducing the exercise intolerance of heart failure patients. These favorable adaptations are achieved, however, on condition that RT is performed at moderate to high intensities (e.g. >75-80% of maximal repetition), intensities that cannot always be sustained by the most fragile and deconditioned patients, such as those with heart failure with reduced ejection fraction. The guidelines recommend intensities of 40% or less of repetition maximum.
Blood flow restriction (BFR) by vascular occlusion training is an interesting alternative to conventional resistance training, particularly for these most deconditioned patients. Preclinical and clinical studies have clearly established that for low-intensity regimens (around 40% of maximal repetition, an intensity well tolerated by the most fragile patients), resistance training+BFR improves muscle strength and left ventricular function, unlike resistance training alone. Tissue hypoxemia, initiated by vascular occlusion and exacerbated by maintenance of exercise, is a key element in the peripheral adaptations documented in BFR, triggering the activation of a cascade of signaling pathways involving neurohumoral factors in particular, with effects both locally (i.e. striated skeletal muscle) and remotely, on the myocardium among others. The feasibility and safety (i.e. no reported adverse events) of BFR in heart failure patients has been well demonstrated.
Left ventricular ejection fraction remains a very global functional index, with poor reproducibility and influenced by cardiac load conditions, making it impossible to draw any conclusions as to possible improvements in myocardial function, linked to changes in intrinsic tissue decontractility/relaxation properties. Innovative cardiac imaging techniques, such as Speckle Tracking Echography, now enable a detailed assessment of the effects of BFR on myocardial function. However, no study has yet used these tools to compare the effects of BFR+resistance training and resistance training alone on myocardial function in heart failure with reduced ejection patients. It is hypothetically suggested that resistance training combined with BFR could further improve cardiac and muscular function compared with resistance training alone, thanks to the activation of neurohumoral mediators, such as certain micro ribonucleic acids.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients on resistance training only. Patients in this group will receive 4 weeks of cardiac rehabilitation with 6 sessions/week, 2 sessions of aerobic training on a cycloergometer and 4 sessions of resistance training
Patients on resistance training combined with blood flow restriction. Sessions will consist of 30 repetitions, followed by 3 sets of 15 repetitions at 40% 1-MR (maximal repetition), interspersed with 60 sec of recovery. An arterial occlusion pressure of 50% of systolic pressure will be maintained constant using a digital tourniquet. The cuff will be deflated during the recovery phases.
Device: Application of a vascular restriction device during resistance training
In the BFR-RT group, sessions will consist of 30 repetitions, followed by 3 sets of 15 repetitions at 40% 1-MR (maximal repetition), interspersed with 60 sec of recovery. An arterial occlusion pressure of 50% of systolic pressure will be maintained constant using a digital tourniquet. The cuff will be deflated during the recovery phases. In the control group (RT group) it will be the same intervention with same intensities but without using BFR.
Also known as: Resistance training
RT control group
Left ventricular global longitudinal strain (GLS), calculated from segmental longitudinal strains on apical 4-, 3-, and 2-chamber views using an 18-segment model (Voigt et al 2015).
Time frame: Baseline
BFR+RT group
Left ventricular global longitudinal strain (GLS), calculated from segmental longitudinal strains on apical 4-, 3-, and 2-chamber views using an 18-segment model (Voigt et al 2015).
Time frame: Baseline
RT control group
Left ventricular global longitudinal strain (GLS), calculated from segmental longitudinal strains on apical 4-, 3-, and 2-chamber views using an 18-segment model (Voigt et al 2015).
Time frame: After 4 weeks of rehabilitation
BFR+RT group
Left ventricular global longitudinal strain (GLS), calculated from segmental longitudinal strains on apical 4-, 3-, and 2-chamber views using an 18-segment model (Voigt et al 2015).
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the control group: Myocardial work
The global index (constructive work, lost work, and efficiency) will be measured in mmHg%
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Myocardial work
The global index (constructive work, lost work, and efficiency) will be measured in mmHg%
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the control group: Myocardial work
The global index (constructive work, lost work, and efficiency) will be measured in mmHg%
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Myocardial work
The global index (constructive work, lost work, and efficiency) will be measured in mmHg%
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the control group: Left atrial deformities
Left atrial deformities will be measured in %
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Left atrial deformities
Left atrial deformities will be measured in %
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the control group: Left atrial deformities
Left atrial deformities will be measured in %
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Left atrial deformities
Left atrial deformities will be measured in %
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the control group: Mechanical dispersion
Post-systolic contractions will be measured in mmHg%
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Mechanical dispersion
Post-systolic contractions will be measured in mmHg%
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the control group: Mechanical dispersion
Post-systolic contractions will be measured in mmHg%
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Mechanical dispersion
Post-systolic contractions will be measured in mmHg%
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the control group: Left ventricle ejection fraction
Left ventricle ejection fraction will be measured in %
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Left ventricle ejection fraction
Left ventricle ejection fraction will be measured in %
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the control group: Left ventricle ejection fraction
Left ventricle ejection fraction will be measured in %
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Left ventricle ejection fraction
Left ventricle ejection fraction will be measured in %
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the control group: E/E' and E/A ratio
E/E' and E/A ratio will be measured
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: E/E' and E/A ratio
E/E' and E/A ratio will be measured
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the control group: E/E' and E/A ratio
E/E' and E/A ratio will be measured
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RTgroup: E/E' and E/A ratio
E/E' and E/A ratio will be measured
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the control group: Cardiac index
Cardiac index will be measured in L/min/m2
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Cardiac index
Cardiac index will be measured in L/min/m2
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the control group: Cardiac index
Cardiac index will be measured in L/min/m2
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Cardiac index
Cardiac index will be measured in L/min/m2
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the control group: Tricuspid regurgitation flow
Tricuspid regurgitation flow will be measured in m/sec
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Tricuspid regurgitation flow
Tricuspid regurgitation flow will be measured in m/sec
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the control group: Tricuspid regurgitation flow
Tricuspid regurgitation flow will be measured in m/sec
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Tricuspid regurgitation flow
Tricuspid regurgitation flow will be measured in m/sec
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the control group: systolic pulmonary arterial pressure
Systolic pulmonary arterial pressure will be measured in mmHg
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: systolic pulmonary arterial pressure
Systolic pulmonary arterial pressure will be measured in mmHg
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the control group: systolic pulmonary arterial pressure (mmHg)
Systolic pulmonary arterial pressure will be measured in mmHg
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: systolic pulmonary arterial pressure (mmHg)
Systolic pulmonary arterial pressure will be measured in mmHg
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the control group: Vmax IT
Vmax IT will be measured in m/sec
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Vmax IT
Vmax IT will be measured in m/sec
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the control group: Vmax IT
Vmax IT will be measured in m/sec
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Vmax IT
Vmax IT will be measured in m/sec
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the control group: Left ventricular volume
Left ventricular telesystolic and telediastolic volumes will be measured
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Left ventricular volume
Left ventricular telesystolic and telediastolic volumes will be measured
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the control group: Left ventricular volume
Left ventricular telesystolic and telediastolic volumes will be measured
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Left ventricular volume
Left ventricular telesystolic and telediastolic volumes will be measured
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the control group: Atrial volume
Atrial telesystolic and telediastolic volumes will be measured
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Atrial volume
Atrial telesystolic and telediastolic volumes will be measured
Time frame: Baseline
(A) other parameters of left ventricular and atrial myocardial function in the control group: Atrial volume
Atrial telesystolic and telediastolic volumes will be measured
Time frame: After 4 weeks of rehabilitation
(A) other parameters of left ventricular and atrial myocardial function in the BFR+RT group: Atrial volume
Atrial telesystolic and telediastolic volumes will be measured
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Myocardial work
The global index (constructive work, lost work, and efficiency) will be measured in mmHg%
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Myocardial work
The global index (constructive work, lost work, and efficiency) will be measured in mmHg%
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Myocardial work
The global index (constructive work, lost work, and efficiency) will be measured in mmHg%
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Myocardial work
The global index (constructive work, lost work, and efficiency) will be measured in mmHg%
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Left atrial deformities
Left atrial deformities will be measured in %
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Left atrial deformities
Left atrial deformities will be measured in %
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Left atrial deformities
Left atrial deformities will be measured in %
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Left atrial deformities
Left atrial deformities will be measured in %
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Mechanical dispersion
Post-systolic contractions will be measured in mmHg%
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Mechanical dispersion
Post-systolic contractions will be measured in mmHg%
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Mechanical dispersion
Post-systolic contractions will be measured in mmHg%
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Mechanical dispersion
Post-systolic contractions will be measured in mmHg%
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Left ventricle ejection fraction
The left ventricle ejection fraction will be measured as a percentage
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Left ventricle ejection fraction
The left ventricle ejection fraction will be measured as a percentage
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Left ventricle ejection fraction
The left ventricle ejection fraction will be measured as a percentage
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Left ventricle ejection fraction
The left ventricle ejection fraction will be measured as a percentage
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: E/E' and E/A ratio
The E/E' and E/A ratio will be measured
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: E/E' and E/A ratio
The E/E' and E/A ratio will be measured
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: E/E' and E/A ratio
The E/E' and E/A ratio will be measured
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: E/E' and E/A ratio
The E/E' and E/A ratio will be measured
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: cardiac index
Cardiac index will be measured in L/min/m2
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: cardiac index
Cardiac index will be measured in L/min/m2
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: cardiac index
Cardiac index will be measured in L/min/m2
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: cardiac index
Cardiac index will be measured in L/min/m2
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Tricuspid regurgitation flow
Tricuspid regurgitation flow will be measured in m/sec
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Tricuspid regurgitation flow
Tricuspid regurgitation flow will be measured in m/sec
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Tricuspid regurgitation flow
Tricuspid regurgitation flow will be measured in m/sec
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Tricuspid regurgitation flow
Tricuspid regurgitation flow will be measured in m/sec
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: systolic pulmonary arterial pressure
Systolic pulmonary arterial pressure will be measured in mmHg
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: systolic pulmonary arterial pressure
Systolic pulmonary arterial pressure will be measured in mmHg
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: systolic pulmonary arterial pressure
Systolic pulmonary arterial pressure will be measured in mmHg
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: systolic pulmonary arterial pressure
Systolic pulmonary arterial pressure will be measured in mmHg
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Vmax IT
Vmax IT will be measured in m/sec
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Vmax IT
Vmax IT will be measured in m/sec
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Vmax IT
Vmax IT will be measured in m/sec
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Vmax IT
Vmax IT will be measured in m/sec
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Atrial volume
Atrial telesystolic and telediastolic volumes will be measured
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Atrial volume
Atrial telesystolic and telediastolic volumes will be measured
Time frame: Baseline
(B) Left cardiac remodeling (left ventricle and atrium) in the control group: Atrial volume
Atrial telesystolic and telediastolic volumes will be measured
Time frame: After 4 weeks of rehabilitation
(B) Left cardiac remodeling (left ventricle and atrium) in the BFR+RT group: Atrial volume
Atrial telesystolic and telediastolic volumes will be measured
Time frame: After 4 weeks of rehabilitation
(C) Stress test measurement in controls : peak oxygen consumption
Peak oxygen consumption (VO2pic) will be measured in mL/min/kg
Time frame: Baseline
(C) Stress test measurement in the BFR+RT group : peak oxygen consumption
Peak oxygen consumption (VO2pic) will be measured in mL/min/kg
Time frame: Baseline
(C) Stress test measurement in controls : peak oxygen consumption
Peak oxygen consumption (VO2pic) will be measured in mL/min/kg
Time frame: After 4 weeks of rehabilitation
(C) Stress test measurement in the BFR+RT group: peak oxygen consumption
Peak oxygen consumption (VO2pic) will be measured in mL/min/kg
Time frame: After 4 weeks of rehabilitation
(C) Stress test measurement in controls : Maximum aerobic power
Maximum aerobic power will be measured in Watts * First ventilatory threshold (SV1) mL/min/kg
Time frame: Baseline
(C) Stress test measurement in the BFR+RT group : Maximum aerobic power
Maximum aerobic power will be measured in Watts * First ventilatory threshold (SV1) mL/min/kg
Time frame: Baseline
(C) Stress test measurement in controls : Maximum aerobic power
Maximum aerobic power will be measured in Watts * First ventilatory threshold (SV1) mL/min/kg
Time frame: After 4 weeks of rehabilitation
(C) Stress test measurement in the BFR+RT group : Maximum aerobic power
Maximum aerobic power will be measured in Watts * First ventilatory threshold (SV1) mL/min/kg
Time frame: After 4 weeks of rehabilitation
(C) Stress test measurement in controls : First ventilatory threshold
First ventilatory threshold will be measured in mL/min/kg
Time frame: Baseline
(C) Stress test measurement in the BFR+RT group : First ventilatory threshold
First ventilatory threshold will be measured in mL/min/kg
Time frame: Baseline
(C) Stress test measurement in controls : First ventilatory threshold
First ventilatory threshold will be measured in mL/min/kg
Time frame: After 4 weeks of rehabilitation
(C) Stress test measurement in the BFR+RT group : First ventilatory threshold
First ventilatory threshold will be measured in mL/min/kg
Time frame: After 4 weeks of rehabilitation
(C) Muscular evaluation in controls: Peak torque
Peak torque will be measured in Nm
Time frame: Baseline
(C) Muscular evaluation in the BFR+RT group: Peak torque
Peak torque will be measured in Nm
Time frame: Baseline
(C) Muscular evaluation in controls: Peak torque
Peak torque will be measured in Nm
Time frame: After 4 weeks of rehabilitation
(C) Muscular evaluation in the BFR+RT group: Peak torque
Peak torque will be measured in Nm
Time frame: After 4 weeks of rehabilitation
(C) Muscular evaluation in controls: Maximum repetition
Maximum repetition will be measured in kilograms
Time frame: Baseline
(C) Muscular evaluation in the BFR+RT group: Maximum repetition
Maximum repetition will be measured in kilograms
Time frame: Baseline
(C) Muscular evaluation in controls: Maximum repetition
Maximum repetition will be measured in kilograms
Time frame: After 4 weeks of rehabilitation
(C) Muscular evaluation in the BFR+RT group: Maximum repetition
Maximum repetition will be measured in kilograms
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in controls: Body mass index
Body mass index will be measured in Kg/m2
Time frame: Baseline
(D) Clinical and biological measurement in the BFR+RT group: Body mass index
Body mass index will be measured in Kg/m2
Time frame: Baseline
(D) Clinical and biological measurement in controls: Body mass index
Body mass index will be measured in Kg/m2
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in the BFR+RT group: Body mass index
Body mass index will be measured in Kg/m2
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in controls: Waist circumference
Waist circumference will be measured in cm
Time frame: Baseline
(D) Clinical and biological measurement in the BFR+RT group: Waist circumference
Waist circumference will be measured in cm
Time frame: Baseline
(D) Clinical and biological measurement in controls: Waist circumference
Waist circumference will be measured in cm
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in the BFR+RT group: Waist circumference
Waist circumference will be measured in cm
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in controls: Lipid profile
Lipids will be measured in mmol/L
Time frame: Baseline
(D) Clinical and biological measurement in the BFR+RT group: Lipid profile
Lipids will be measured in mmol/L
Time frame: Baseline
(D) Clinical and biological measurement in controls: Lipid profile
Lipids will be measured in mmol/L
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in the BFR+RT group: Lipid profile
Lipids will be measured in mmol/L
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in controls: Glycated hemoglobin
Glycated hemoglobin will be measured as a %
Time frame: Baseline
(D) Clinical and biological measurement in the BFR+RT group: Glycated hemoglobin
Glycated hemoglobin will be measured as a %
Time frame: Baseline
(D) Clinical and biological measurement in controls: Glycated hemoglobin
Glycated hemoglobin will be measured as a %
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in the BFR+RT group: Glycated hemoglobin
Glycated hemoglobin will be measured as a %
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in controls: Fasting blood glucose
Fasting blood glucose will be measured in g/L
Time frame: Baseline
(D) Clinical and biological measurement in the BFR+RT group: Fasting blood glucose
Fasting blood glucose will be measured in g/L
Time frame: Baseline
(D) Clinical and biological measurement in controls: Fasting blood glucose
Fasting blood glucose will be measured in g/L
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in the BFR+RT group: Fasting blood glucose
Fasting blood glucose will be measured in g/L
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in controls: Pro-Brain Natriuretic Peptide
Pro-Brain Natriuretic Peptide will be measured in ng/L
Time frame: Baseline
(D) Clinical and biological measurement in the BFR+RT group: Pro-Brain Natriuretic Peptide
Pro-Brain Natriuretic Peptide will be measured in ng/L
Time frame: Baseline
(D) Clinical and biological measurement in controls: Pro-Brain Natriuretic Peptide
Pro-Brain Natriuretic Peptide will be measured in ng/L
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in the BFR+RT group: Pro-Brain Natriuretic Peptide
Pro-Brain Natriuretic Peptide will be measured in ng/L
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in controls: C-reactive protein
C-reactive protein will be measured in mg/L
Time frame: Baseline
(D) Clinical and biological measurement in the BFR+RT group: C-reactive protein
C-reactive protein will be measured in mg/L
Time frame: Baseline
(D) Clinical and biological measurement in controls: C-reactive protein
C-reactive protein will be measured in mg/L
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in the BFR+RT group: C-reactive protein
C-reactive protein will be measured in mg/L
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in controls: Micro ribonucleic acids
Micro ribonucleic acids will be measured in ng/µl
Time frame: Baseline
(D) Clinical and biological measurement in the BFR+RT group: Micro ribonucleic acids
Micro ribonucleic acids will be measured in ng/µl
Time frame: Baseline
(D) Clinical and biological measurement in controls: Micro ribonucleic acid
Micro ribonucleic acids will be measured in ng/µl
Time frame: After 4 weeks of rehabilitation
(D) Clinical and biological measurement in the BFR+RT group: Micro ribonucleic acid
Micro ribonucleic acids will be measured in ng/µl
Time frame: After 4 weeks of rehabilitation
(E) MacNew Heart Disease Quality of Life score in controls
The MacNew is a self-administered heart disease-specific health-related quality of life \[HRQL\] questionnaire which addresses 3 major HRQL domains: Emotional, Physical, and Social. Each domain contains 9 questions to be rated as 1 \[not very important\] to 5 \[very important\]. These domains can be combined to give a Global HRQL score
Time frame: Baseline
(E) MacNew Heart Disease Quality of Life score in the BFR+RT group
The MacNew is a self-administered heart disease-specific health-related quality of life \[HRQL\] questionnaire which addresses 3 major HRQL domains: Emotional, Physical, and Social. Each domain contains 9 questions to be rated as 1 \[not very important\] to 5 \[very important\]. These domains can be combined to give a Global HRQL score
Time frame: Baseline
(E) MacNew Heart Disease Quality of Life score in controls
The MacNew is a self-administered heart disease-specific health-related quality of life \[HRQL\] questionnaire which addresses 3 major HRQL domains: Emotional, Physical, and Social. Each domain contains 9 questions to be rated as 1 \[not very important\] to 5 \[very important\]. These domains can be combined to give a Global HRQL score
Time frame: After 4 weeks of rehabilitation
(E) MacNew Heart Disease Quality of Life score in the BFR+RT group
The MacNew is a self-administered heart disease-specific health-related quality of life \[HRQL\] questionnaire which addresses 3 major HRQL domains: Emotional, Physical, and Social. Each domain contains 9 questions to be rated as 1 \[not very important\] to 5 \[very important\]. These domains can be combined to give a Global HRQL score
Time frame: After 4 weeks of rehabilitation
(F) International Physical Activity Questionnaire in controls
The International Physical Activity Questionnaire is intended for people aged 15 and over. The questionnaire assesses overall physical activity and sedentary time over the last seven days. The questionnaire looks at vigorous and moderate activity, walking, and time spent sitting (sedentary lifestyle), whether during leisure activities, at work, in daily life or during transport. There are several versions of the questionnaire, including a short one (7 questions) and a long one (27 questions), which people can self-administer or answer by telephone, for example. The questionnaire classifies the subject according to 3 levels of activity: inactive, moderate, high.
Time frame: Baseline
(F) International Physical Activity Questionnaire in the BFR+RT group
The International Physical Activity Questionnaire is intended for people aged 15 and over. The questionnaire assesses overall physical activity and sedentary time over the last seven days. The questionnaire looks at vigorous and moderate activity, walking, and time spent sitting (sedentary lifestyle), whether during leisure activities, at work, in daily life or during transport. There are several versions of the questionnaire, including a short one (7 questions) and a long one (27 questions), which people can self-administer or answer by telephone, for example. The questionnaire classifies the subject according to 3 levels of activity: inactive, moderate, high.
Time frame: Baseline
(F) International Physical Activity Questionnaire in controls
The International Physical Activity Questionnaire is intended for people aged 15 and over. The questionnaire assesses overall physical activity and sedentary time over the last seven days. The questionnaire looks at vigorous and moderate activity, walking, and time spent sitting (sedentary lifestyle), whether during leisure activities, at work, in daily life or during transport. There are several versions of the questionnaire, including a short one (7 questions) and a long one (27 questions), which people can self-administer or answer by telephone, for example. The questionnaire classifies the subject according to 3 levels of activity: inactive, moderate, high.
Time frame: After 4 weeks of rehabilitation
(F) International Physical Activity Questionnaire in the BFR+RT group
The International Physical Activity Questionnaire is intended for people aged 15 and over. The questionnaire assesses overall physical activity and sedentary time over the last seven days. The questionnaire looks at vigorous and moderate activity, walking, and time spent sitting (sedentary lifestyle), whether during leisure activities, at work, in daily life or during transport. There are several versions of the questionnaire, including a short one (7 questions) and a long one (27 questions), which people can self-administer or answer by telephone, for example. The questionnaire classifies the subject according to 3 levels of activity: inactive, moderate, high.
Time frame: After 4 weeks of rehabilitation
Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 24 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Aug 2025 → Dec 2025, primary completion Aug 2027 → Dec 2027 and completion Sep 2027 → Jan 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nīmes →